Refining the risk of HTLV-1-associated myelopathy in people living with HTLV-1: identification of a HAM-like phenotype in a proportion of asymptomatic carriers.
HTLV-1
HTLV-1-associated myelopathy
Proviral load
T-cell activation markers
β2 microglobulin
Journal
Journal of neurovirology
ISSN: 1538-2443
Titre abrégé: J Neurovirol
Pays: United States
ID NLM: 9508123
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
16
11
2021
accepted:
07
07
2022
revised:
22
03
2022
pubmed:
31
7
2022
medline:
31
12
2022
entrez:
30
7
2022
Statut:
ppublish
Résumé
Up to 3.8% of human T-lymphotropic virus type-1 (HTLV-1)-infected asymptomatic carriers (AC) eventually develop HTLV-1-associated myelopathy (HAM). HAM occurs in patients with high (> 1%) HTLV proviral load (PVL). However, this cut-off includes more than 50% of ACs and therefore the risk needs to be refined. As HAM is additionally characterised by an inflammatory response to HTLV-1, markers of T cell activation (TCA), β
Identifiants
pubmed: 35908019
doi: 10.1007/s13365-022-01088-x
pii: 10.1007/s13365-022-01088-x
pmc: PMC9797460
doi:
Substances chimiques
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
473-482Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
© 2022. The Author(s).
Références
J Med Virol. 2012 Apr;84(4):664-71
pubmed: 22337307
Lancet. 1989 Nov 18;2(8673):1184-7
pubmed: 2572904
Lancet. 1986 May 3;1(8488):1031-2
pubmed: 2871307
J Acquir Immune Defic Syndr (1988). 1990;3(11):1096-101
pubmed: 2213510
Lancet. 1992 May 2;339(8801):1110
pubmed: 1349119
Front Microbiol. 2012 Nov 15;3:388
pubmed: 23162541
Neurology. 2003 Dec 9;61(11):1588-94
pubmed: 14663047
J Infect Dis. 2006 Dec 1;194(11):1557-64
pubmed: 17083040
Neurol Neuroimmunol Neuroinflamm. 2021 Oct 5;8(6):
pubmed: 34611039
Lancet. 1990 Dec 1;336(8727):1345-7
pubmed: 1978165
PLoS Negl Trop Dis. 2019 May 1;13(5):e0006967
pubmed: 31042700
J Neurovirol. 1998 Dec;4(6):586-93
pubmed: 10065900
J Med Virol. 2014 Feb;86(2):315-21
pubmed: 24027213
J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Feb 1;17(2):167-70
pubmed: 9473019
Clin Infect Dis. 2015 Jul 1;61(1):49-56
pubmed: 25820277
Ann Rheum Dis. 1997 Mar;56(3):167-72
pubmed: 9135218
Rev Inst Med Trop Sao Paulo. 2007 Jul-Aug;49(4):231-3
pubmed: 17823752
J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):92-100
pubmed: 10534152
BMC Infect Dis. 2014 Aug 22;14:453
pubmed: 25148903
J Med Virol. 2011 Jul;83(7):1269-74
pubmed: 21567429
Lancet. 1985 Aug 24;2(8452):407-10
pubmed: 2863442
Braz J Infect Dis. 2012 Jul-Aug;16(4):357-60
pubmed: 22846124
Inflamm Allergy Drug Targets. 2008 Jun;7(2):98-107
pubmed: 18691139
Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80
pubmed: 7031654
AIDS Res Hum Retroviruses. 2013 Feb;29(2):359-64
pubmed: 22894552
Retrovirology. 2011 Oct 12;8:81
pubmed: 21992623
Acta Neurol Scand Suppl. 1997;169:86-93
pubmed: 9174644
Clin Infect Dis. 2012 Jan 1;54(1):43-50
pubmed: 22095566
Scand J Immunol. 2002 Jun;55(6):621-8
pubmed: 12028566
J Gen Virol. 2005 Mar;86(Pt 3):773-781
pubmed: 15722539
J Med Virol. 1992 Oct;38(2):138-41
pubmed: 1460458
J Neuroimmunol. 1989 Dec;25(2-3):251-4
pubmed: 2584397